Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504556 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,146
- Enrollment target
NCT00504556 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,146 participants.
The verdict
NCT00504556, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,146 participants
- Enrollment target
Study Summary
This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.
Interventions
- DRUG warfarin
- DRUG Edoxaban (DU-176b)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,146 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00504556
The ClinicalTrials.gov registry entry for NCT00504556 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which warfarin is the first listed.
NCT00504556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00504556 about?
NCT00504556 is a clinical study titled "A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation". This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.
What is the current status of trial NCT00504556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,146 participants. The study started on 2007-06. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00504556?
The interventions under investigation include: warfarin (DRUG), Edoxaban (DU-176b) (DRUG).
Who is sponsoring clinical trial NCT00504556?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.